ArticleJournal of orthopaedic surgery and research2025
Geniposide ameliorates cholesterol accumulation and promotes osteoblast differentiation by mediating the GLP-1R/AMPK/SREBP2 pathway.
Article in Journal of orthopaedic surgery and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Glucagon-like peptide-1: a critical link between gut microbiota dysbiosis and degenerative musculoskeletal diseases.Gut microbes · 2026Review
- Stage-dependent endoplasmic reticulum homeostasis in osteogenic differentiation.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundGlucocorticoid (GC)-induced OP (GIOP) is a systemic metabolic bone disease with a high risk of fracture. Recently, lipid metabolic disorders, particularly hypercholesterolemia, have been correlated to the development of OP. However, the roles of cholesterol accumulation in osteoblasts during GIOP pathological development are still unclear. Our previous study shows that intracellular cholesterol accumulation can suppress osteoblast differentiation and promote cell apoptosis. Geniposide (GEN), a natural activator of glucagon-like peptide-1 receptor (GLP-1R), exhibited protective activity against dexamethasone (DEX)-induced cholesterol accumulation and osteoblast differentiation inhibition. Sterol regulatory element-binding protein 2 (SREBP2) regulates cholesterol synthesis. Whether SREBP2 was involved in DEX-induced cholesterol accumulation and osteoblast differentiation was still unknown.
methodsDEX-induced rat OP models were duplicated. Micro-computed tomography (µCT) was used to scan the proximal femurs, and hematoxylin and eosin (H&E) staining was used for histological examination. MC3T3-E1 cells were used for the cell study, and ALP and Alizarin Red S were employed to study osteoblast differentiation. pcDNA3.1-SREBP2 was used to transfect MC3T3-E1 cells. Western blotting assays were employed to study the protein expression.
resultsDEX enhanced the expression of SREBP2 and mTOR and promoted cholesterol accumulation and osteoblast differentiation inhibition in MC3T3-E1 cells. These could be rescued by GEN treatment. However, overexpression of SREBP2, mTOR activation, and AMPK and GLP-1R inhibition could block the protective effects of GEN.
conclusionGEN improved DEX-induced cholesterol accumulation and osteoblast differentiation inhibition by mediating the GLP-1R/AMPK/mTOR/SREBP2 signaling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.